EP Patent

EP1585525B1 — Use of thiazolobenzoheterocycles for treating multiple sclerosis

Assigned to Aventis Pharmaceuticals Inc · Expires 2010-11-17 · 15y expired

What this patent protects

The invention relates to the use of compound of Formula I in treating patients for inflammatory or neuropathic pain as well as various symptoms of multiple sclerosis

USPTO Abstract

The invention relates to the use of compound of Formula I in treating patients for inflammatory or neuropathic pain as well as various symptoms of multiple sclerosis

Drugs covered by this patent

Patent Metadata

Patent number
EP1585525B1
Jurisdiction
EP
Classification
—
Expires
2010-11-17
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.